cas 35251-84-4|| where to buy Pyrido[3,4-b]pyrazine-2,3(1H,4H)-dione

Nombre del producto:Pyrido[3,4-b]pyrazine-2,3(1H,4H)-dione

IUPAC Name:1H,2H,3H,4H-pyrido[3,4-b]pyrazine-2,3-dione

Unidad de embalaje	Stock disponible	Precio($)
CM214023-1g	in stock	ǪǙ
CM214023-5g	1-2 Weeks	Ōħħ
CM214023-25g	1-2 Weeks	ľǙǸ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 35251-84-4 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :35251-84-4; Fórmula molecular:C7H5N3O2; Punto de fusión:-; Código de sonrisas:O=C1NC=2C=NC=CC2NC1=O; Densidad:

: Número de catálogo:CM214023; Peso molecular:163.14; Punto de ebullición:; Nº Mdl:MFCD01411816; Almacenamiento:

: Quinazolines; Quinazolines belong to heterocyclic chemistry, also known as 1,3-naphthalenes. The backbone consists of two six-membered aromatic rings fused to each other, with two nitrogen atoms at positions 1 and 3 on the backbone. The presence of these two nitrogen atoms in quinazoline increases its importance in pharmaceutical and biological reactions. Quinazolines and their derivatives are among the most important heterocyclic compounds due to their diverse chemical reactivity and important range of biological activities.

: CVN424; In a Phase 2 clinical trial, CVN424, a novel, non-dopaminergic, GPR6 inverse agonist, demonstrated a significant reduction in OFF time and was safe and well tolerated with low rates of mostly mild and moderate adverse events. Patients also reported enhanced motor functionality in daily activities, as assessed by the UPDRS Part II. These findings enhance the confidence in CVN424's potential to address both motor and non-motor symptoms of Parkinson’s disease, consistent with observations in pre-clinical models, potentially heralding a transformative non-dopaminergic therapy.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.